Compounds > 4-butyrolactone
Page last updated: 2024-08-18

4-butyrolactone and Anochlesia

4-butyrolactone has been researched along with Anochlesia in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19902 (25.00)18.7374
1990's4 (50.00)18.2507
2000's1 (12.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maher, TJ; Phattanarudee, S; Towiwat, P1
Coop, A; Koek, W; Mercer, SL1
Beales, M; Lorden, JF; McKeon, TW; Oltmans, GA; Walkley, SU1
Bearden, LJ; Snead, OC1
Hirose, T; Kikuchi, T; Miwa, T; Morita, S; Oshiro, Y; Tottori, K; Uwahodo, Y1
Carruba, MO; da Prada, M; Imhof, R; Nisoli, E; Scherschlicht, R; Tonello, C1
Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y1
Coward, DM; Dixon, AK; Enz, A; Karobath, M; Shearman, G; Urwyler, S; White, TG1

Other Studies

8 other study(ies) available for 4-butyrolactone and Anochlesia

ArticleYear
Comparative study of equimolar doses of gamma-hydroxybutyrate (GHB), 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL) on catalepsy after acute and chronic administration.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 51

    Topics: 4-Butyrolactone; Animals; Area Under Curve; Butylene Glycols; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Male; Mice; Sodium Oxybate; Toxicity Tests, Acute; Toxicity Tests, Chronic

2013
Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
    Psychopharmacology, 2007, Volume: 192, Issue:3

    Topics: 4-Butyrolactone; Animals; Baclofen; Catalepsy; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GABA-B Receptor Agonists; Male; Mice; Mice, Inbred C57BL; Narcolepsy; Organophosphorus Compounds; Receptors, GABA-B; Sodium Oxybate; Substance-Related Disorders

2007
Decreased catalepsy response to haloperidol in the genetically dystonic (dt) rat.
    Brain research, 1984, Aug-06, Volume: 308, Issue:1

    Topics: 4-Butyrolactone; Aging; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Dystonia; Golgi Apparatus; Haloperidol; Humans; Morphine; Neurons; Rats; Rats, Mutant Strains; Receptors, Muscarinic; Species Specificity

1984
Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate.
    Neurology, 1980, Volume: 30, Issue:8

    Topics: 4-Butyrolactone; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine; Electroencephalography; Epinephrine; Furans; Humans; Male; Naloxone; Naltrexone; Rats

1980
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:1

    Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Male; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Piperazines; Presynaptic Terminals; Quinolones; Radioligand Assay; Rats; Reserpine; Spiperone; Stereotyped Behavior; Synapses; Tritium

1995
Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 266, Issue:1

    Topics: 4-Butyrolactone; Adenylyl Cyclases; Amphetamine; Animals; Apomorphine; Biogenic Monoamines; Brain; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Locomotion; Male; Motor Activity; Perfusion; Potassium; Quinolines; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Serotonin; Stereotyped Behavior; Synapses; Tetrahydronaphthalenes; Time Factors; Tritium

1993
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
    Journal of medicinal chemistry, 1998, Feb-26, Volume: 41, Issue:5

    Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship

1998
Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
    The Journal of pharmacology and experimental therapeutics, 1990, Volume: 252, Issue:1

    Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Behavior, Animal; Catalepsy; Dopamine; Dopamine Agents; Ergolines; Female; Male; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine

1990